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Introduction
The World Health Organization (WHO) has set the goal of eliminating hepatitis as a threat to public health by 2030, which includes reducing the prevalence of hepatitis B surface antigen (HBsAg) among children to 0.1%. 1 Mother to child transmission (MTCT) is the major route of hepatitis B virus (HBV) transmission, accounting for 40%-50% of chronic infections worldwide. 2 Therefore, blocking MTCT of HBV will be the key step in achieving this goal.
The mainstay of preventing hepatitis B acquisition at birth comprises at least 3 doses of hepatitis B vaccine, including a birth dose administered in a timely manner, i.e., within 24 hours of birth. 3 Active-passive immunoprophylaxis through use of hepatitis B immune globulin (HBIG) is recommended among infants born to women with chronic HBV infection. 4 Although recent studies suggest that vaccine alone may be as effective as the combination of vaccine and HBIG in preventing infection among neonates born to HBsAg-positive/Hepatitis B e antigen (HBeAg) -negative women, the current standard recommendations include the use of HBIG for the prevention of MTCT. 5, 6 Known factors that increase the risk of MTCT include HBeAg positivity, high viral load among pregnant women, and instrumental deliveries at birth. [7] [8] [9] M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 In the last two decades, multiple studies have documented the use of telbivudine (LdT) or tenofovir disoproxil fumarate (TDF) in reducing the risk of HBV MTCT. A systematic review suggested that antiviral therapy, compared to the administration of HBIG and vaccination, improved HBV suppression and reduced MTCT in women with a high viral load. 10 Other studies noted the demonstrated effectiveness of antiviral therapy during the late stage of pregnancy in preventing MTCT among women with a high viral load. [11] [12] [13] [14] [15] However, there remains uncertainty regarding the effect of antiviral drug use, as a recent multicenter, randomized, double-blinded clinical trial conducted in Thailand by Jourdain et al. 16 did not show a significant difference in MTCT rate between the intervention and control arms.
Several sets of guidelines, including those of the American Association for the Study of
Liver Diseases (AASLD), 17 the European Association for the Study of the Liver (EASL), 18 and the Asian Pacific Association for the Study of the Liver (APASL), 19 and National Institute for Health and Care Excellence (NICE) 20 recommend consideration of antiviral use among pregnant women with chronic HBV infection. The 2015 WHO guidelines for the treatment of hepatitis B do not formally recommend the use of antiviral agents for the prevention of MTCT due to the limited quantity and low quality of supporting evidence, comparison of antivirals, evaluation of potential harms, real-world studies and programmatic implications based on the GRADE review used by the WHO. 21 In China, various practices of antiviral drug use are implemented to prevent HBV MTCT.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 8 To harmonize and standardize clinical management to prevent MTCT of hepatitis B, several meetings were coordinated by the China Foundation for Hepatitis Prevention and Control (CFHPC), bringing together experts from across the country in infectious diseases, hepatology, immunology, obstetrics and public health (the "Group") to design a consensus protocol for clinical practice based on reviewing major international and Chinese guidelines and current global evidence.
The practice protocol for the care of HBsAg-positive pregnant women and their infants is as follows:
1.Testing and diagnosis
Following the current national recommendations of the National Health Committee, all pregnant women should be screened for hepatitis B, syphilis, and HIV at the first prenatal examination and/or as early as possible during antenatal care. 22 The Group recommends that the HBV serologic marker HBsAg be tested as part of the screening. If test result for 
Initial assessment (baseline) and management decisions
The Group recommends staging of liver disease status for HBsAg-positive pregnant women to determine the degree of liver injury. Baseline tests include maternal HBV viral load (HBV DNA), HBV serologic markers, liver function tests, and upper abdominal ultrasound.
Management decisions should consider the following:
2.1 In HBeAg-positive pregnant women with HBV DNA >20,000 IU/mL or HBeAg-negative pregnant women with HBV DNA >2,000 IU/mL and significant hepatic activity, alanine aminotransferase (ALT) ≥5×upper limit of normal (ULN) (excluding other potential etiologies), or liver cirrhosis, the consideration in starting antiviral therapy is the woman's health. The drug of choice is TDF, which should be prescribed after clinical assessment, counselling, patient's education and receipt of informed consent by specialists in hepatology or infectious diseases. The decision to start antiviral treatment and the plan for patient management should be communicated to the obstetric team. accordingly. In addition, total bilirubin and prothrombin activity should be tested to evaluate the severity of liver disease.
Management during pregnancy
In pregnant women with normal or slightly elevated ALT, HBV DNA should be quantified with the sensitive method of real-time polymerase chain reaction (PCR) in the second trimester. For the prevention of HBV MTCT, antiviral treatment should be considered based on HBV DNA quantification.
3.1 If HBV DNA is above 2×10 6 IU/mL, antiviral treatment with either TDF or LdT (A1) [11] [12] [13] [14] [15] should be administered after patient education and informed consent at gestational week 24-28. The risks and benefits and the limited evidence for this approach should be discussed with the patient. The benefit of antiviral treatment is to protect the newborns from LdT has no influence on congenital abnormalities or neonatal growth percentiles. However, it should be noted that, in an HIV/AIDS cohort study, 24 in utero exposure to TDF resulted in a 12% reduction in total mean whole-body bone mineral content (56.0 g vs 63.8 g; P=.002). Moreover, the rate of postpartum hepatic flare was reported to be 40%-50% in mothers who stopped antiviral treatment. 25 Accumulating studies have demonstrated that treatment using TDF or LdT during the third trimester is effective and safe for the prevention of MTCT in mothers with high viral loads, [11] [12] [13] [14] [15] and this approach has been recommended by major guidelines. [17] [18] [19] [20] 23 Although Jourdain's study in Thailand did not demonstrate a statistically significant benefit of TDF treatment over a placebo control, the findings might not be generalizable to other countries.
Given the potentially insufficient sample size and relatively high rate of loss to follow-up in the study, the difference between the TDF (0%) and placebo (2%) arms could hardly be differentiated. In pregnant women with very high baseline viral loads (≥1×10 8 IU/mL),
earlier initiation of antiviral therapy may be necessary to achieve viral suppression below the recommended threshold. 26 Before delivery, HBV DNA quantification should be repeated to evaluate the efficacy of antiviral therapy and the risk of MTCT.
3.2 If the HBV DNA level is ≤ 2×10 6 IU/mL, antiviral therapy is not recommended. 23 Considering that the threshold of antiviral therapy to prevent MTCT is variable among current guidelines (Table 1) Immunoprophylaxis to be delivered at birth, including the hepatitis B vaccine and HBIG, should be provided. The skin at the injection rite should be cleaned with an alcohol swab before the injection is administered.
Discontinuation of antivirals
For pregnant women who have normal ALT levels and receive antiviral therapy to prevent MTCT during pregnancy, drugs can be discontinued immediately after delivery (B2). 23, 25 Close monitoring of maternal ALT is warranted after withdrawal of antivirals because postpartum hepatitis may occur. The details of follow-up are described in section 10.2.
The appropriate time to discontinue antivirals is still controversial among current guidelines M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 14 because there is not sufficient evidence on this issue. In most studies on antiviral therapy during pregnancy to prevent MTCT, maternal antiviral therapy was discontinued at 1-3 months after delivery to avoid ALT flares. Based on these studies, the EASL guidelines recommend that antiviral therapy be stopped up to 12 weeks after delivery for pregnant women who receive antivirals to prevent MTCT. 18 However, extension of antiviral therapy for several weeks or months has not been shown to significantly prevent the occurrence of postpartum hepatitis flare. 25 Therefore, the Chinese Medical Association guidelines suggest that maternal antiviral therapy can be discontinued at delivery and that regular monitoring of the ALT should be performed to detect postpartum hepatitis flares. 23 It was reported that ALT flares occurred more frequently in mothers who had previously taken TDF than in those who had not received TDF (45% vs 30%). 13 Although postpartum hepatitis is often mild in severity and is usually resolved spontaneously, severe ALT flares were observed in approximately 5% of mothers after discontinuation of antivirals. 13 Care should be taken to address the possibility of severe hepatitis, even fulminant hepatitis. As the existing evidence is limited and insufficient, well-designed studies are needed to ascertain the appropriate time to stop antiviral therapy. breastfeeding is not contraindicated (C2). It has been reported that, in the breast milk of TDF-treated mothers, the drug is present only at low concentrations, and its oral bioavailability is limited; thus, infants are exposed to only a minuscule amount of TDF. 30 age. 31 The assessment of PVST is described, along with corresponding measures, in the following section.
Follow-up of infants

Assessment of PVST for HBV-exposed infants
PVST examines two markers, namely, HBsAg and anti-HBs (antibody levels), which allow clinicians to determine whether an infant is immune and protected, infected, or uninfected and nonimmune. Quantification of anti-HBs antibody levels will help clinicians determine whether an infant is protected; the threshold of protection is defined as ≥10 mIU/mL. Among infants born to HBsAg+ mothers, the rate of non/low response to hepatitis B vaccine was reported to be 22.4% -30.2% compared to 5%-10% in general infant's population. [32] [33] [34] [35] The risk factors of non/low response to hepatitis B vaccine include high HBV DNA level, premature labor, low birth weight, type of hepatitis B vaccine etc. 36, 37 Several studies showed that additional doses of hepatitis B vaccine could induce robust anti-HBs response in most of low-responding infants. 38, 39 Additional single dose of 10 µg hepatitis B vaccine should be administrated to low-responding infants, given the immune response of low-responding infants might be unstable and the potential risk of horizontal infection still exist under the circumstance of close contact between mother and infant.
Further studies are needed to investigate the effectiveness of booster dose for low-responding infants. 1
Follow-up of mothers after delivery
Weaker
With more variability in preferences and values or greater uncertainty, a weak recommendation is more likely to be warranted. Recommendations with higher costs or resource consumption are also made with less certainty. 
